An ultra-scalable biomanufacturing platform for personalized regenerative medicines

What is the Challenge?

Treatments using stem cells created from a patient's own cells, known as autologous induced pluripotent stem cells (iPSC), are showing great potential for treating various medical conditions. This approach, which falls under personalized regenerative medicine, could be key in not just managing but possibly curing diseases such as Parkinson's, heart disease, and age-related vision loss. However, the challenge lies in the fact that the current methods of producing these treatments are labor-intensive and handcrafted, making it difficult to produce them on a large scale to meet the demand of many patients.

What is the Solution?

Cellino is building an ultra-scalable biomanufacturing platform to manufacture iPSCs to unlock personalized, affordable regenerative medicine treatments for a range of diseases affecting hundreds of millions of patients. The company’s platform combines advanced biology, precise lasers, image-guided artificial intelligence, and a robust software infrastructure to manufacture high-quality cells autonomously.

Cellino’s bioprocess is designed to enhance batch-to-batch efficiency and patient-to-patient reliability via autonomous iPSC biomanufacturing in a closed growth chamber—without open cell transfers that risk cell damage and contamination. This enables a patient-specific, sealed “cassette” that forms the basis for highly scalable manufacturing. The background image on this page shows the design for a future version ofCellino’s modular biomanufacturing system, which will enable the processing of thousands of patient samples simultaneously.